Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

OBJECTIVE: This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patient...

詳細記述

書誌詳細
主要な著者: Kasper, S, Hajak, G, Wulff, K, Hoogendijk, W, Montejo, A, Smeraldi, E, Rybakowski, J, Quera-Salva, M, Wirz-Justice, A, Picarel-Blanchot, F, Baylé, F
フォーマット: Journal article
言語:English
出版事項: 2010